#1 Clinical Trials Search in Europe

Fremanezumab

Fremanezumab is an investigational drug being studied in clinical trials for the prevention and treatment of various headache disorders, primarily migraine. This article summarizes key findings from recent clinical trials evaluating the safety and efficacy of fremanezumab for conditions like chronic and episodic migraine, cluster headache, post-traumatic headache, and other pain disorders. The trials examine different dosing regimens and patient populations to determine the optimal use of fremanezumab as a preventive therapy.

Table of Contents

What is Fremanezumab?

Fremanezumab is a medication used for the prevention of migraine headaches. It is also known by the brand name Ajovy and was previously referred to as TEV-48125 during its development[1]. Fremanezumab belongs to a class of drugs called monoclonal antibodies, which are laboratory-produced molecules designed to serve as substitute antibodies that can restore, enhance, or mimic the immune system’s attack on specific cells[2].

What Conditions Does Fremanezumab Treat?

Fremanezumab is primarily used for the prevention of migraine headaches in adults. It has been studied and shown effective for both episodic migraine (EM) and chronic migraine (CM)[2]. Here’s a breakdown of the conditions:

  • Episodic Migraine (EM): This is defined as having fewer than 15 headache days per month[3].
  • Chronic Migraine (CM): This is characterized by 15 or more headache days per month[2].
  • Menstrually-related Migraine: Fremanezumab is being studied for its effectiveness in treating migraines related to menstrual cycles[4].
  • Post-Traumatic Headache (PTH): Research is ongoing to evaluate fremanezumab’s efficacy in treating headaches that occur after traumatic brain injuries[5].
Additionally, researchers are exploring the potential of fremanezumab in treating other conditions such as:
  • Cluster Headache: A rare but extremely painful type of headache[6].
  • Fibromyalgia: A condition characterized by widespread musculoskeletal pain[7].
  • Interstitial Cystitis-Bladder Pain Syndrome (IC-BPS): A chronic condition causing bladder pressure and pain[8].

How Does Fremanezumab Work?

Fremanezumab works by targeting a protein called calcitonin gene-related peptide (CGRP). CGRP is involved in pain signaling and inflammation in the brain, particularly during migraine attacks. By binding to CGRP, fremanezumab prevents it from attaching to its receptors, thereby reducing the frequency and severity of migraine headaches[2].

How is Fremanezumab Administered?

Fremanezumab is administered as a subcutaneous (under the skin) injection. The dosing schedule can vary depending on the specific treatment plan:

  • Monthly dosing: Some patients receive a single injection every month[1].
  • Quarterly dosing: Other patients may receive three injections once every three months[1].
The exact dose may be adjusted based on the patient’s weight, especially in pediatric patients[9]. It’s important to note that fremanezumab is typically administered by a healthcare professional, but in some cases, patients or caregivers may be trained to give the injections at home.

Efficacy of Fremanezumab

Clinical trials have shown promising results for fremanezumab in reducing the frequency and severity of migraine headaches. Some key findings include:

  • Reduction in monthly migraine days: Patients treated with fremanezumab experienced a significant decrease in the number of days they had migraines each month[2].
  • Decreased use of acute headache medications: Fremanezumab treatment led to a reduction in the need for other medications to treat acute headache symptoms[2].
  • Improved quality of life: Many patients reported improvements in their ability to function and their overall quality of life while using fremanezumab[2].
It’s important to note that the effectiveness of fremanezumab can vary from person to person. Some patients may see improvements within the first month of treatment, while others may need several months to experience significant benefits.

Safety and Side Effects

Fremanezumab has been generally well-tolerated in clinical trials. However, like all medications, it can cause side effects. Common side effects may include:

  • Injection site reactions: Such as pain, redness, or swelling where the injection was given[2].
  • Allergic reactions: In rare cases, some patients may experience allergic reactions to fremanezumab[2].
During clinical trials, researchers closely monitored various safety aspects, including:
  • Changes in laboratory values: Such as blood tests to check liver and kidney function[2].
  • Cardiovascular effects: Monitoring of heart rate and blood pressure[2].
  • Suicidal ideation: While rare, researchers monitored for any changes in mood or thoughts of self-harm[3].
It’s crucial to discuss any side effects or concerns with your healthcare provider. They can help determine if the benefits of fremanezumab outweigh any potential risks for your specific situation.

Fremanezumab in Special Populations

Researchers are studying the use of fremanezumab in various patient groups:

  • Pediatric patients: Clinical trials are underway to evaluate the safety and efficacy of fremanezumab in children and adolescents aged 6 to 17 years[9][3].
  • Patients with treatment-resistant migraine: Studies are examining fremanezumab’s effectiveness in patients who haven’t responded well to other preventive treatments[2].
  • Women with menstrually-related migraine: Research is ongoing to determine if fremanezumab is particularly effective for migraines associated with menstrual cycles[4].
These studies aim to provide more targeted treatment options for different patient groups and expand our understanding of how fremanezumab can be used most effectively.

Ongoing Research

Fremanezumab continues to be the subject of numerous clinical trials and research studies. Some areas of ongoing investigation include:

  • Long-term safety and efficacy: Researchers are conducting studies to evaluate the long-term effects of fremanezumab use, some lasting up to 7 years[9].
  • Use in other conditions: As mentioned earlier, studies are exploring fremanezumab’s potential in treating conditions like fibromyalgia and interstitial cystitis[7][8].
  • Comparison with other treatments: Ongoing research is comparing fremanezumab to other migraine prevention treatments to determine its relative effectiveness[2].
  • Personalized medicine approaches: Scientists are investigating factors that might predict which patients will respond best to fremanezumab treatment[2].
These ongoing studies aim to refine our understanding of fremanezumab and potentially expand its use to help more patients suffering from migraine and other related conditions.

Aspect Details
Drug Name Fremanezumab (also known as TEV-48125, Ajovy)
Drug Class Monoclonal antibody targeting calcitonin gene-related peptide (CGRP)
Primary Indications Migraine prevention (chronic and episodic)
Other Potential Indications Cluster headache, post-traumatic headache, menstrually-related migraine, fibromyalgia, interstitial cystitis
Administration Subcutaneous injection (monthly or quarterly dosing)
Key Efficacy Outcomes Reduction in monthly migraine days, reduction in headache days of moderate-to-severe intensity, decreased use of acute migraine medications
Safety Profile Generally well-tolerated; common side effects include injection site reactions
Ongoing Research Long-term safety and efficacy, use in specific populations (e.g. pediatric, treatment-resistant), optimal dosing regimens

FAQ

  • What is fremanezumab and how does it work? Fremanezumab is a monoclonal antibody that targets calcitonin gene-related peptide (CGRP), a protein involved in migraine pathophysiology. It works by binding to CGRP and preventing it from activating its receptors, which is thought to reduce the frequency and severity of migraine attacks.
  • What conditions is fremanezumab being studied for in clinical trials? Fremanezumab is primarily being studied for migraine prevention in adults with chronic or episodic migraine. It is also being investigated for other headache disorders like cluster headache, post-traumatic headache, and menstrually-related migraine. Some trials are exploring its potential in treating fibromyalgia and interstitial cystitis as well.
  • How is fremanezumab administered in clinical trials? In most trials, fremanezumab is administered as a subcutaneous injection. The dosing regimens being studied include monthly injections (e.g. 225 mg every 4 weeks) and quarterly injections (e.g. 675 mg every 12 weeks). The specific dose and frequency can vary based on the trial design and patient population.
  • What are some of the main outcomes being measured in fremanezumab clinical trials? Key outcomes include change in monthly migraine days, proportion of patients achieving 50% or greater reduction in migraine days, change in headache days of moderate-to-severe intensity, use of acute migraine medications, disability scores, quality of life measures, and safety/tolerability endpoints like adverse events and development of anti-drug antibodies.
  • Are there any notable side effects or safety concerns with fremanezumab in clinical trials? Fremanezumab has generally been well-tolerated in clinical trials. Common side effects include injection site reactions. Trials are monitoring for potential risks like cardiovascular effects, liver toxicity, and development of anti-drug antibodies. Long-term safety data is still being collected in ongoing studies.

Ongoing Clinical Trials on Fremanezumab

  • Study on Reducing Chronic Migraine Days with CGRP Antibodies and Botulinum Toxin A in Adults Aged 18-70

    Recruiting

    1 1 1
    Investigated drugs:
    Norway

  • Study on Fremanezumab for Pain Relief in Patients with Complex Regional Pain Syndrome

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study on the Effectiveness of Fremanezumab for Preventing Migraines in Children and Teens Aged 6 to 17

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Finland Germany Italy The Netherlands Poland Spain

  • Study on Migraine: Effects of Fremanezumab on Brain Chemistry in Patients with and without Aura

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Austria

Glossary

  • Migraine: A neurological condition characterized by recurrent moderate to severe headaches, often accompanied by other symptoms like nausea, sensitivity to light and sound, and visual disturbances called aura.
  • Chronic migraine: A condition where a person experiences 15 or more headache days per month, with at least 8 of those days meeting criteria for migraine, for more than 3 months.
  • Episodic migraine: Migraine that occurs less frequently than chronic migraine, typically 14 or fewer headache days per month.
  • Calcitonin gene-related peptide (CGRP): A protein involved in pain signaling and inflammation, thought to play a key role in migraine. Fremanezumab targets and blocks this protein.
  • Monoclonal antibody: A type of protein made in the laboratory that can bind to specific substances in the body. Fremanezumab is a monoclonal antibody designed to bind to CGRP.
  • Subcutaneous injection: An injection given into the fatty tissue just beneath the skin. This is how fremanezumab is typically administered in clinical trials.
  • Anti-drug antibodies (ADAs): Antibodies produced by the body's immune system in response to a therapeutic drug. Development of ADAs is monitored in clinical trials as they can potentially impact drug efficacy or safety.
  • Placebo: An inactive substance that looks like the drug being tested. Used in clinical trials to help determine if the effects seen with the active drug are due to the drug itself or other factors.
  • Double-blind study: A type of clinical trial where neither the participants nor the researchers know who is receiving the active drug versus placebo. This helps reduce potential bias in assessing outcomes.
  • Open-label study: A type of clinical trial where both the researchers and participants know which treatment is being administered. Often used to gather long-term safety data.

References

  1. https://clinicaltrials.gov/study/NCT05458011
  2. https://clinicaltrials.gov/study/NCT03308968
  3. https://clinicaltrials.gov/study/NCT04458857
  4. https://clinicaltrials.gov/study/NCT06659120
  5. https://clinicaltrials.gov/study/NCT03347188
  6. https://clinicaltrials.gov/study/NCT03107052
  7. https://clinicaltrials.gov/study/NCT03965091
  8. https://clinicaltrials.gov/study/NCT04447729
  9. https://clinicaltrials.gov/study/NCT04530110